Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Authors:
Open Access
- 9 December 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1248-1257
Abstract
Context: Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective: The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO. Methods: A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16. Results: Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered. Conclusion: Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.Keywords
Funding Information
- Novartis Pharma
This publication has 35 references indexed in Scilit:
- Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and managementThe Lancet Diabetes & Endocrinology, 2025
- Inflammatory and tolerogenic dendritic cells and T lymphocytes in Graves' thyroidal and orbital diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2025
- Redox mechanisms in autoimmune thyroid eye diseaseAutoimmunity Reviews, 2024
- A Novel Monoclonal Antibody Degrades the Thyrotropin Receptor Autoantibodies in Graves' DiseaseEndocrine Practice, 2023
- Drug safety in thyroid eye disease – a systematic reviewExpert Opinion on Drug Safety, 2022
- Pathophysiology of thyroid-associated orbitopathyBest Practice & Research Clinical Endocrinology & Metabolism, 2022
- Secukinumab: A Review in Psoriatic ArthritisDrugs, 2021
- Secukinumab: A Review in Ankylosing SpondylitisDrugs, 2019
- Increased serum interleukin-17 in Graves’ ophthalmopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2012
- Quality of Life in a German Graves Orbitopathy PopulationAmerican Journal of Ophthalmology, 2011